Site tools

• Skip to content
• Vision impaired
• Login
• Links
• Glossary
• Contact
• Sitemap
• Site help
• Advanced search
• Accessibility
• Disclaimer

You are here

Navigation

• NICE guidance by type
  • Cancer service guidance
  • Clinical guidelines
  • Interventional procedures
  • Public health guidance
  • Technology appraisals
    • Published appraisals
    • Appraisals in development
    • Proposed appraisals
• NICE guidance by topic
• NICE guidance by date
• Other publications
• Order NICE guidance
• NICE guidance research recommendations
• Patient safety solutions pilot

Breast cancer (early) - paclitaxel

• Guidance chapters
• Table of Contents
• Selection
• Help

Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

Chapter : 1. Guidance2. The technology3. The manufacturer’s submission4. Consideration of the evidence5. Implementation6. Related NICE guidance7. Proposed date for review of guidanceAppendix A: Appraisal Committee members, guideline representatives and NICE project teamAppendix B: Sources of evidence considered by the Committee

1. Guidance

1.1. Paclitaxel, within its licensed indication, is not recommended for the adjuvant treatment of women with early node-positive breast cancer

 

 

• Accessibility
• Cymraeg
• Freedom of Information
• Data Protection
• Copyright
• Disclaimer
• NHS Choices

Copyright © 2010 National Institute for Health and Clinical Excellence. All rights reserved.